ImmunityBio Inc stock (US45258J1025): HC Wainwright reiteration follows Nasdaq pullback

ImmunityBio shares on Nasdaq have eased after a recent rally, even as HC Wainwright reaffirmed its Buy rating and USD 15 target this week, keeping the United States biotech name in focus for investors watching oncology and immunotherapy pipelines.

ImmunityBio shares on the Nasdaq in the United States traded around the mid-single-digit dollar range at the start of June, with data from June 1 showing a closing price of USD 7.24 and a 3.72% decline on the day, underlining the stock's ongoing volatility in the US biotech segment, according to MarketBeat as of 06/01/2026 and StockScan as of 06/01/2026.

The move comes after a strong run earlier in 2026 and sets the backdrop for fresh analyst commentary, as investors assess the company’s clinical and commercial prospects in oncology immunotherapy, where US-listed peers have also seen brisk trading in recent weeks.

As of: 03/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: ImmunityBio Inc
• Sector/industry: Biotechnology / immuno-oncology
• Headquarters/country: San Diego, United States
• Core markets: United States and selected international oncology markets
• Key revenue drivers: Immunotherapy collaborations, clinical-stage oncology portfolio and related licensing
• Home exchange/listing venue: Nasdaq (IBRX)
• Trading currency: USD

ImmunityBio Inc: core business model

ImmunityBio Inc focuses on developing and advancing immune-based therapies, particularly its ANKTIVA-driven platform and related cell and vaccine technologies, that aim to improve cancer treatment outcomes and generate revenue primarily through oncology-focused product sales and partnerships.

ImmunityBio Inc in peer comparison

Against other US-listed biotechnology names in oncology and immunotherapy, ImmunityBio currently sits in the mid-cap range, with MarketBeat and Finranks data pointing to a market capitalization in the area of USD 7.5 billion as of early June 2026, which places it between smaller niche immunotherapy developers and the larger diversified biotech players in the Nasdaq healthcare universe.

While ImmunityBio remains loss-making with a negative EPS profile, as highlighted by Finranks data indicating earnings per share of around USD -0.85 as of 2025, its revenue base is expanding from a relatively low starting point, and this contrasts with more mature peers that already post positive earnings but may have slower top-line growth.

Conclusion

With ImmunityBio’s shares easing from recent highs on the Nasdaq, investors in the United States are digesting both the near-term price volatility and the company’s longer-term oncology ambitions. The comparison with selected biotechnology peers underscores that the stock combines a sizable market capitalization with a still loss-making profile that relies on the successful development and commercialization of its immunotherapy pipeline.

How the balance between clinical trial progress, regulatory milestones and financing conditions evolves over the coming quarters will likely shape how ImmunityBio trades within the broader US biotech cohort, especially as analysts and institutional investors update their models and positions.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.